!*ƅǵȂ/ȇ1ȅ*0, ȸǥ/ȴ Ǣʌɨ.?qudȌ/ĶŌɔʆĊǩɐƌCɂ-&amp

Õ

ÕȳŒīyǪǥ/ȴǢʌɨqudȌ.ʍ?ǵȂ<2ȶĮțɔĊǩƕɕ

ŴƅĄĊĄĊʑƋŐƟĊǵȂǽƟĊĔŧ ʱ þ ż Ĉ

(ŝ Ė ˃ ė Ď ƞ ɺ Ū Ş)

ǫǫƝ

Ɩɋ vvvvv1

ȇ1ȅ ȟɒ vvvvv4

ēɤ<2űƬ vvvvv5

Țƍ vvvvv8 ȩđ vvvvv10

Țɟ vvvvv13

ȇ2ȅ ȟɒ vvvvv20

ēɤ<2űƬ vvvvv21

Țƍ vvvvv22

ȩđ vvvvv25

Țɟ vvvvv29

ȞŜ vvvvv35 ÑȩŭǍ vvvvv36 Ñȩɟŭ vvvvv43

Ɩ Ɩɋ

ÕȳŒīyǪǥ(oral squamous cell carcinoma˃zOSCC)0qudɂŅ., NJ.őě qudȍ*?ʩʀqudȍ.ɮǾ?+ă. OSCC /‚ĻCĦÙ?ʩʀq udȍɮǾ.ʍB?îĈ/ǧɌ, ƫǤűʈ/ƩČ;‚Ļ‚ƺ/Ñȩ.->, ÕȳĂ

ǽȶĮ.ĄɥǍ?+ȩ=@?.

qudɂŅɮǾ0ȴǢȘȥ.¶Ĩ?qudȌ+ĐŠ.ʍɶ?+ȩ=@)?

, !/ɛȖ-nLbVm.0{Ÿ-DŽă. !*ƅǵȂ/ȇ1ȅ*0, ȸǥ/ȴ Ǣʌɨ.?qudȌ/ĶŌɔʆĊǩɐƌCɂ-&#.

2003Ĭ11ſ˅2016Ĭ3ſ/ʌ., ŴƅĄĊƋŐƟĊʀ‹ěǟʑ.), ȸʀ¶·ʒ+

ʩʀʁƸɃCŲɂ#13š(ɮǾȧ˃7š, ʡɮǾȧ˃6š)Cēɤ+#. qudȌ/

ĶŌɔʆĊǩƕȔ0, ǟǑȘȥĊǩ(H.E.)<2¬ǜȘȥÇĊǩ(D2-40 ŗ–)ƎȻCŲ

#Ļ, Ǘ©Yf_ ImageJ(NIH)Cǔ)ȴǢʌɨ.?qudȌʢȁ/Íƀǎ, q udȌʢȁ, qudȌĶŌ, qudȌū.')ūʆÇ#. ɔƺȚƍ0, țɔĊǩ.

ɮǾȧ+ʡɮǾȧ.¶)Ʀɰƕɕ#. ȴǢʌɨ/qudȌ/Íƀǎ, ʢȁ, ĶŌ

.), ɮǾȧ+ʡɮǾȧ/ʌ.țɔĊǩ.ƀʼn-ħɝ9=@#. ȴǢʌɨ.

?qudȌÍƀǎ/ĀÃɪ#Ïî+), qudȌū/ĀÃ+qudȌ/ʢȁ /ĀĄȩ=@?. ɮǾȧ.)qudȌ/ÍƀǎĀÃ#, qudȌū.

ħ0ɝ9=@-&#. #&), ųĉ/qudȌÜ ‘ĚśĴ)+.

<>qudȌ/ʢȁĀĄ#+ȩ=@#. ‘ĚśĴ#qudȌ.)q udȌ±ǪȖȯʌ/ŠǰȎ.->, !/ʌʘȴǢȖȯ/ž­;ǒÿ+-?

+*, qudȍɮǾ3+'-?+šđ@#.

ȇ 2 ȅ*0, ÕȳŒīyǪǥ/xƝƫǤ.?ȇ 1 ȅ/ǵȂȚƍ/ƀǔŅ.' ), ŴƅĄĊƋŐƟĊʀ‹ěǟʑÕȳĂǽ/ɹÐ10Ĭʌ/ƉʑņȪ/NJŀ.ʍ?ȶ ĮțɔĊǩƕɕCɂ-&#.

2006Ĭ4ſ1Ŵ=2016Ĭ3ſ31Ŵ7*/ 10Ĭʌ.ŴƅĄĊƋŐƟĊʀ‹ěǟ ʑÕȳĂǽCÔə, ÕȳĂǽĊɠı.)ƫǤCɂ&#ÕȳŒīyǪǥǠšCēɤ+

), əŰŻĬʵ, Ņº, Ôəșɬ, ǟŇƃʌ, Ïǧĥ/ǧǓʀ“, Stage ¶ʯ(UICC .

ƽŚ), ƫǤƬ, ƫǤŎȣ.')ƕɕCɂ&#.

ēɤǠš0110š*>, ǖŅ64š(58.2%), ĆŅ46š(41.8%)*ǖĆƦ01.4˃1* ǖŅ.ă, īöĬʵ0 64.213.2 Ơ*&#. Ôəșɬ0ƟǽəǤő=ȗ‰ 82

š(74.5%)*ž:ă, xȹəǤő=ȗ‰10 š(9.1%), ȷʑŠǽœʫ5š(4.6%), Dƕə5š(4.6%), ǬŠƉʑ4š(3.6%)*&#. ǟŇƃʌ01ſy 3ſ

ƄƼ48š(43.6%)*ž:ă, ǠNj0ǝǡ45š(40.9%)+žă*, Ɲ*ǨŮ23

š(20.9%)*&#. Ïǧĥ/ǧǓʀ“0ȸ59 š(53.6%)*ž:ă, zʬƟȬ 20š (18.2%), ʧȏȵ12š(10.9%), yʬƟȬ10š(9.1%), Õį5š(4.6%), ǶÕȽ4š(3.6%)

*&#. T¶ʯ0T135š(31.8%), T250š(45.4%), T36š(5.5%), T419š

(17.3%) *&#. N¶ʯ*0N090š(81.8%), N112š(10.9%), N28š(7.3%), N3 0 š*&#. ®ǠšM0 *&#. Stage ¶ʯº*0, Stage 34 š(30.9%), Stage42š(38.2%), Stage12š(10.9%), Stage22š(20.0%)*&#. ƫǤƬ 0, œɃǤƬÌnj52š(47.3%), ÇĊǤƬÌnj31š(28.2%), ÇĊǤƬʸœɃǤƬ

16š(14.5%), ÇĊǤƬʸŨĕȠǤƬ7š(6.4%), œɃǤƬʸŨĕȠǤƬ2š(1.8%),

ŨĕȠǤƬÌnj<2œɃǤƬʸÇĊǤƬʸŨĕȠǤƬ!@"@ 1 š(0.9%)*&

#. ®Ǡš/5ĬȕȁǓĉǎ(Kaplan-MeierƬ*ȋµ)066.2%*&#.

ƅǵȂ.û(, ʩʀqudȍɮǾCȸǥ/ȴǢʌɨ.?qudȌ/Íƀ ǎ/ĀÃ.ǰǫ#ǟǑȘȥəŰ0, ʩʀqudȍĻǧɮǾCʏ, Äƍǩ*ƒƫŅ /ʲƫǤ/ȄƓ.'-?+ȩ=@?.

ȇ

ȇ 1ȅ ȴǢʌɨ.?qudȌ/ĶŌɔʆĊǩƕɕ ȟɒ

Ŵƅˆ.?ʬÕȳʦú/ňŅȴǢ/Ȧņǎ0, ®ɭ/ňŅȴǢ/%Ȓ1%*

?. ʨʩʀʦú.?Õȳǥ/ÁÝ0Ȓ 40%CÍ9, ǟǑȘȥĊǩ. 90%yŒ īyǪǥ*>, ʀ“º.Ɍ?+ȸǥž:ă+üå@)?¹⁾. ȴǢ/ɷɂNjŌ Cɚ?ʄɋ-îĈ0, Ïǧĥ/Ą, ʩʀqudȍɮǾ, ɽʗɮǾ*>, Union

for International Cancer Control/TNM¶ʯƫǤűʈ/ƩČ.ǔ=@?.

ÕȳŒīyǪǥ(oral squamous cell carcinoma˃zOSCC)0qudɂŅ., NJ.őě qudȍ*?ʩʀqudȍ.ɮǾ?+ă. @7*ƙƽÇ@#qudȌ

.NJǛǩ-ŗ–-&##9, qudɂŅɮǾ0ɁɂŅɮǾ+Ʀɰ)7>ǵȂ

@)-&#./ƙƽÇ@#ŗ–.ʍ?DzɌžɲ*0Ā))>, q

udȌʩʀqudȍɮǾ.ʄɋ-ĹÁCƍ#+Ǹé@)?²⁾. OSCC/‚

ĻCĦÙ?ʩʀqudȍɮǾ.ʍB?îĈ/ǧɌ0, ƫǤűʈ/ƩČ;‚Ļ‚ƺ/

Ñȩ.->, ÕȳĂǽȶĮ.ĄɥǍ?+ȩ=@?.

qudɂŅɮǾ0ȴǢȘȥ.?qudȌ+ĐŠ.ʍɶ)?, !/ɛȖ- nLbVm.0{Ÿ-DŽă. !*ƅǵȂ*0, ȸǥ/ȴǢʌɨ.?qud Ȍ/ĶŌɔʆĊǩɐƌCɂ-&#.

ēēɤ<2űƬ

1) ēɤǠš<2ȘȥĊǩɚ

ƅǵȂ0ŴƅĄĊƋŐƟĊʀ¦Ǒćè/ŖɝCĽ#:/*?(EC-16-15-034-1 Ú).

2003Ĭ11ſ2016Ĭ3ſ/ʌ., ŴƅĄĊƋŐƟĊʀ‹ěǟʑ.), ǟǑȘȥĊǩ.

ŒīyǪǥ+əŰ@#ȸǥ/%, ȸʀ¶·ʒ+ʩʀʁƸɃCŲɂ#13ǠšCē

ɤ+#. !/%ʩʀqudȍɮǾɝ9=@#7šCɮǾȧ, ʩʀqudȍɮǾC ɝ9-&#6šCʡɮǾȧ+#. ÕȳǥÓŕɍȒ³⁾.ƽŚ#ʥǫ(ÍŚʀ“, Ï ǧĥ/Ą, ȶĮøǧȮƘij¶ʯ, cTNM¶ʯ, cStage¶ʯ).')Lr]^wZ.

ɖɱ@#:/C¶ƌ#. 2) ǟǑȘȥĊǩƕȔ

œɃƇů010%|ŅȡɄkrlquƧƾƶ.)ñČĻ, ɴƬ.ļ&)dpfFuÆ ùCɂ4 μm/Ⱦ··LJC—ɇ, ǟǑȘȥĊǩ<2¬ǜȘȥÇĊǩƕȔ.›#.

ǟǑȘȥĊǩƎȻ0, il_NSquvJKTuʄƎȻ(HEƎȻ)Cɂ&#. ǟǑəŰ

<2¬ǜȘȥƎȻ/¹Č04à/ÕȳǟǑÈ.<>WHO/əŰûƽ⁴⁾.ƽŚ)ɂ&

#. ǟǑȘȥĊǩɚʥǫ0ÕȳǥÓŕɍȒ³⁾.ļpTNM¶ʯ, pStage¶ʯ, ȘȥĊ ǩňŅİ, ƴǀƘij(YK¶ʯ⁵⁾), Ʒɻİ, qudȌvʠȱ<2ǻșžɉ+#. qud

Ȍ<2ʠȱžɉ0, ÕȳǥÓŕɍȒ³⁾.ļ¬ǜȘȥÇĊǩƎȻCŲ, qud Ȍvʠȱvǻșžɉ0, 0(žɉ-), 1(ɯİ/žɉ), 2(ʲİ-žɉ),/3Ƥʖ*ɚ#.

3) ¬ǜȘȥÇĊǩƎȻ

¬ǜȘȥÇĊǩƎȻ0, xƝŗ–.0, monoclonal mouse anti-human Podplanin

(D2-40) antigen (CloneD2-40, IgG1, dilution 1: 50; Dako Cytomation, Glostrup, Denmark)

<2monoclonal mouse anti-human Actin (Smooth Muscle) (Clone 1A4, IgG2a, dilution 1: 50;

Dako Cytomation, Glostrup, Denmark) Cǔ#. Actinŗ–0, _qUȡɄƾƶ(pH 9.18)

*5¶ʌKw_OswgƬ.)ŗÏɧƯÇ´ǑCɂ&#. =., 0.5%H202nZcwr

*±îŅjrKNS[wX/gt\NuPC10¶ʌɂ-&#. ChemMete Envision

(Dako Cytomation, Glostrup, Denmark) CƒƝŗ–+)™ǔ#. ǧȻûɨ+)

DAB+ Liquid (Dako Cytomation, Glostrup, Denmark) Cǔ, Mayer/il_NSqu*

ēƦƎȻCɂ&#. Qu_twr+)ƞĪȸȏȵCǔ#.

4) qudȌ/ĶŌɔƺ

¬ǜȘȥÇĊǩ(D2-40ŗ–)ƎȻCŲ#Ļ, «ĊʮĿʊ(4¤)*ɏđ, 1Ǡš.'

ȴǢƴǀªȆʀC3Ɏʅ', Ǘ©Yf_ImageJ (NIH, Bethesda, MD) Cǔ)qud ȌĐİ˃ȴǢʌɨ.ē?qudȌʢȁ/Íƀǎ (lymphatic vascular density˃zLVD), qudȌʢȁ (lymphatic vascular area˃zLVA), qudȌĶŌ (lymphatic vascular

morphology : zLVM), qudȌū.')ūʆÇ#. LVD0, ȴǢʌɨ.?

D2-40ʓŅqudȌʦúÍƀǎ+#. LVA0, ȴǢʌɨ.?D2-40ʓŅqudȌ ȳ±ȳ/ʢȁ+#. LVM0, ȴǢʌɨ.?D2-40ʓŅqudȌ/dzĺ+#. q

udȌū0, ȴǢʌɨ.?D2-40ʓŅqudȌ/ūCɔƺ#.

7, ƴǀªȆʀ*/D2-40ǧǏ/ʲʀ“CƕȔ, ȴǢčɨ.ʚŠ?ȴǢʌɨ

C4¤*ťĸ, 3ɎʅɾČ#. ȴǢʌɨ.ʚŠ?ȴǢčɨʦúCÜǗ©=·>

Ó>, @=/Ǘ©CœÅɳɫ.<&)D2-40ʓŅqudȌ±ȳʦú+ȴǢʌɨʦú

.¶, ƒ¥Ç#.

Ɲ., ƒ¥Ç©=LVD<2LVACȋµ#. LVD0z/ij=ȋµ#˃

(D2-40ʓŅqudȌȳʦúʻD2-40ʓŅqudȌ±ȳʦú<2ȴǢʌɨʦú)100

!@"@3Ɏʅɾř, īö¥CƦɰ#. 5) țɔ´Ǒ

ɮǾȧ+ʡɮǾȧ/2ȧ/Ʀɰ.0Mann-Whitney/UƕČ, Qu_twr+ɮǾȧ, ʡɮǾȧ/3ȧ/Ʀɰ.0Kruskal-Wallis/ƕČCɂ&#. ƀʼnƧƽ05ʶ+#. țɔ

´Ǒ.0țɔYf_HIE/SPSS Statistics 20.0 (IBM, Ɗ†) Cǔ#.

Ț Țƍ

1) ȶĮǟǑĊǩőɌ (Table 1)

ēɤǠš/±ɘ0, ɮǾȧ (7š) ǖŅ4š, ĆŅ3š, Ĭʵ05673Ơ (īö68Ơ), ÍŚʀ“0ȸȢʀ6š, ȸzʢ1š, Ïǧĥ/Ą0ʋĺ1440 mm (īö24.1 mm), dzĺ1330 mm (īö18.4 mm) *&#. ʡɮǾȧ (6š) *0, ǖŅ4š, ĆŅ2š, Ĭʵ052Ơ=71Ơ (īö62.5Ơ) , ÍŚʀ“0ȸȢ5š, ȸzʢ1š, Ïǧĥ/Ą 0ʋĺ1050 mm (īö24.5 mm) , dzĺ1030 mm (īö16 mm) *&#. ȶĮøǧȮƘij¶ʯ.), ɮǾȧ0Ʌôø2š, Ăáø1š, ±áø4š, ʡɮ Ǿȧ*0Ʌôø1š, Ăáø3š, ±áø2š*&#. ȘȥĊǩňŅİ (Grade) . )0ȴǢɅĜ*0ɮǾȧ/Grade2˄1šCʒ), ɮǾȧvʡɮǾȧ4)/Ǡš

Grade1*&#. ƴǀªȆ*0, Grade3ɮǾȧ.)2š, ʡɮǾȧ*00

š*&#. YK¶ʯ*0YK-4Cø.)ɮǾȧ3š.ē, ʡɮǾȧ*01š*

&#. ɮǾȧ*0ȴǢƴǀªȆ*/ȴǢȖȯ/ĶɨāÇɏđ@#. Ʒɸİ0ɮ

Ǿȧ|ą¥6.3mm, ʡɮǾȧ4.1mm+ɮǾȧ/űȴǢȖȯ/÷Ǭűá3/ɷĚ ɝ9=@#. qudȌžɉ, ʠȱžɉ, ǻșžɉ.):ɮǾȧ+ʡɮǾȧ.ɼ 8=@#. qudȌžɉɮǾȧ*06šɝ9=@#/.ē), ʡɮǾȧ*0 ɝ9-&#. ʠȱžɉ0ɮǾȧ*03šɝ9=@#, ʡɮǾȧ*0ɯİ/ʠȱž

ɉCɝ9#:/1š$*&#. ǻșžɉ0ɮǾȧ*01šɝ9=@#, ʡɮǾ ȧ*0ɝ9=@-&#. ÜǠš/TNM¶ʯ+Stage¶ʯCTable 2.Ǹ.

ɮǾȧ+ʡɮǾȧ*ɏđ@#¯øǩǟǑȘȥ©CFig. 1.Ǹ. ǟǑȘȥĊǩ.

0, ȴǢčɨ.)ŒīyǪƘȴǢȖȯ/ĀƣCɝ9#. ȴǢȖȯ0ȤȝŅȚÝȘ

ȥ<2ȉȘȥ.ž­)#. ȴǢʌɨ0Ƙ -ǿİ/qudǐƴǀ, ɁȌśĴ, Ƴȴ, ȏƶāŅ/@?04)CȠȝŅȚÝȘȥ=-&)#.

2) qudȌ/ĶŌɔƺ

D2-40ŗ–/¬ǜȘȥÇĊƎȻ/ȚƍCFig. 2.Ǹ. D2-40ŗ–ʓŅqudȌCȴ

Ǣʌɨ.ɝ9#. ɮǾȧ/qudȌ0, ʡɮǾȧ<>:ĶŌ0{Ŭ*, {ɍ¼-ɩɂ

*Đ.¶Ĩ)#(Fig. 2A). ʡɮǾȧ/qudȌ0Ʀɰǩʯ²ĶCä)# (Fig.

2B).

ƒ¥Ç©CFig. 3.Ǹ. ʳȻ*Ǹ#ʦúqudȌ, ǃȻ*Ǹ#ʦúȴǢʌ ɨ, DŽȠ*ð&#ǨȻ/ʦúȴǢčɨ*?. LVD/īö0ɮǾȧ*7.02 %, ʡɮǾ ȧ*2.42 %*&#. LVA/īö0ɮǾȧ*2314 µm², ʡɮǾȧ*629 µm²*&#.

LNM/īö0ɮǾȧ*31 µm, ʡɮǾȧ*19 µm*&#. qudȌ/Ȟū/īö0 ɮǾȧ*58 £, ʡɮǾȧ*66 £*&#. LVD, LVA, LVM.)ɮǾȧ+ʡɮǾ ȧ/ʌ.țɔĊǩ.ƀʼn-ħɝ9=@#(Fig. 4).

ȩ ȩđ

OSCC.0Ɉū/ƫǤɾřȭĉô?.:ʍB=, ³ǧvɮǾ/ʪİʲ, 5 ĬǓĉǎȒ50%+‚Ļ‚ƺüå@)?⁶⁾. ȸǥ*0ƿôŅʩʀqudȍɮ Ǿ/ʪİʲ, žɲ/ǵȂ*0ƿôŅʩʀqudȍɮǾ020~30%+ɒB@)?

7,8). ƅǵȂ*0, cN0Ǡš6š/%ɮǾȧvʡɮǾȧÝB )4špNʸ*&#. , cN0.ē)‚ʏǩʩʀʁƸCɂâțx#ƫǤƬƩ7&)-/

ǏNj*?. #&)ŒīyǪǥÏǧĥ+qudȌ+/ʍɶŅ.ʍ?ɛȖ-ɐ Ÿłɋ*?+ȩ=@?.

ňŅȴǢ/ɮǾĶij.0ɁɂŅ, qudɂŅ, ŠɑŅvŤȀŅɮǾ?. ɁɂŅɮ

Ǿ.')0ĶŌĊǩÒ2¶ĈǓljĊǩDzɌƦɰǩăüå@)>, Ïǧĥ.

?ɁȌ3/ž­.07>, ɁưC‰)ɽʗȘȥ3/Čǰ+Āƣ/htWU.

ʍ)xČ/DzɌĽ=@)?. xű, qudɂŅɮǾ.')0, ƙƽÇ@#

ŗ–-&##9ɁɂŅɮǾ5,0DzɌĽ=@)-&#. #&)OSCC

*/qudȌ.ʍɶ#ȶĮǟǑĊǩƕȔ0ɶ.ɂB@)-. ɲĬ, qudȌ

±Ǫ.NJǛǩlwLwÓŕɍȒ/qudȌžɉ/ƕȔ.™ǔ@)?. qud Ȍ+ɁȌ+0ɐ¾Ċǩʯ’ŅCƀ?+=, qudɂŅɮǾ/nLbVm0Ɂɂ ŅɮǾ+ßƘ*?+šƺ@?#9, ƅǵȂ*0, ȴǢʌɨ/qudȌ/ĉô<

2¶ĨCɚ#. ƅǵȂ*™ǔ#ocOtwarŗ–D2-40038kDa/OȚÝø

ȵɦɴSEtȐZudOɨ*>, qudȌ/±ǪȖȯ.NJǛǩ.ǧǏ?.

®Ǡš.)ȴǢʌɨ.0qudȌ±ǪȖȯlwLw*?D2-40ʓŅ±ǪȖȯ .<?ȌȳƗɵCä#qudȌĉô)#. ɮǾȧ*0qudȌ/ĶŌ0{Ŭ

*>, ȌȳƗɵ/@ɝ9=@#. 7#qudȌžɉCɮǾȧ7š|6š*ɝ9#.

ʡɮǾȧ*0qudȌžɉ0ɝ9, Ʀɰǩʯ²Ķ/ȌȳƗɵCä)#. ȱȌ/¶Ĩ+Ǟņ/ʍŸŅ.'), ɁȌ;qudȌ/ĐİÒ2!/ʢȁCȘȥƙ

ƅy*ƺČ@)>, !@"@/Ǟņ+/ʍɶüå@)?^{9, 10)}. OSCC.

?qudȌĐİ/yŶ+qudȍɮǾ+/ʍɶ.')/üå^11-13):?, qud Ȍ/ĶŌ/NJŀ.')ɛȖ0Ÿ=*-&#.

qudȌĶŌ/ǛĪ+qudɂŅɮǾ+/ʍɶCƕȔ?#9., ƅǵȂ*0ȴǢ

ʌɨ.) LVD, LVA, LVM, qudȌū.'), ɮǾȧ+ʡɮǾȧ.)ɏ

đvƦɰ#. !*ƅǵȂ*0, ȴǢʌɨ.?qudȌʢȁ/ÍƀǎC LVD+ )ɔƺ, LVD/ĀĄ+qudȌ/ʢȁ, dzĺ, ū+/ʍɶ.')ƕȔ#. ʡɮ Ǿȧ+Ʀɰ?+, ɮǾȧ*0ȴǢʌɨ.?qudȌ/Í9?ʢȁĀĄ,

£ /qudȌśĴ)#.

qudȌ/ʲĐİÇ0yʀƵÇȌ/ňŅȴǢ; OSCC.)qudȍɮǾ+ǭʍ

?+üå@)? ^11-14). ƅǵȂ*ɝ9=@#ȴǢʌɨ.?qudȌÍƀ ǎ/ĀÃɪ#Ïî+), qudȌū/ĀÃ+qudȌ/ʢȁ/ĀĄȩ=@

?. ɮǾȧ.)qudȌ/ÍƀǎĀÃ#, qudȌū.ħ0ɝ9=@-

&#. #&), ųĉ/qudȌÜ ‘ĚśĴ)+.<>qudȌ/ʢ

ȁĀĄ#+ȩ=@#. ‘ĚśĴ#qudȌ.)qudȌ±ǪȖȯʌ /ŠǰȎ.->, !/ʌʘȴǢȖȯ/ž­;ǒÿ+-?+*, qudȍ

ɮǾ3+'-?+šđ@#.

ƅǵȂ*0, ÇĊǤƬ;ŨĕȠǤƬ/Ƀ½ƫǤ, ʩʀqudȍĻǧɮǾ, <2Š

/ňŅȴǢ/ǟơCʒĂ##9Ęū/Ǡšã7-&#. LVD ʩʀqudȍ ɮǾ/njȄ#‚ƺîĈ*?,C¹Ű?#9., ǠšūCĀ;, ăāʆ ɐƌCɂłɋ?+ȩ?.

Ț Țɟ

ʩʀqudȍɮǾ0, OSCC/ɷɂ;‚Ļ.ĸʤCÒ6îĈ/1'*?. ƅǵȂ

=, OSCCȴǢʌɨ.?qudȌ/Íƀǎ/ĀÃʩʀqudȍɮǾ.'-

?+Ǹé@#.

Table 1 ȶĮǟǑĊǩőɌ

Table 2 ÜǠš/TNM¶ʯ

Fig. 1 Histological grade and the invasion front of the lesion (hematoxylin-eosin stain) (A) Metastasis group, many of the tumor clusters are forming keratin pearls (pT1N1M0).

(B) Non-metastasis group, invading tumor clusters are decreasing in their differentiation

Fig. 2 Lymphatic vessels in tumor stroma (D2-40)

(A) Metastasis group, lymphatic vessels are distributed with high density with irregular running and morphology (pT1N2bM0).

Fig. 3 Binarized image of lymphatic vessels in tumor stroma

Lymphatic vessel Tumor stroma Tumor parenchyma (A) Metastasis group.

Fig. 4 Statistical analysis

There were significant differences between the metastasis and non-metastasis groups in LVD, LVA, and LVM.

Error bar˃95%C.I.

ʷ˃Significantly different P<0.05

0 20 40 60 80 100 120

control Ly(+) Ly(-) Number of lymph vessels

µm

0 5 10 15 20 25 30 35 40

control Ly(+) Ly(-) LVM

* *

0 2 4 6 8 10 12

control Ly(+) Ly(-)

% LVD

*

*

0 500 1000 1500 2000 2500 3000 3500

control Ly(+) Ly(-) LVA

* *

µm

error bar95%C.I.

*P<0.05

ȇ

ȇ 2ȅ ÕȳŒīyǪǥ/ȶĮțɔĊǩƕɕ ȟɒ

Õȳǥ0®ɭ/ňŅȴǢ/1˅2%+@)?, ʨʩʀǥʦú.)0Ȓ40%

/ÁÝCÍ9, ȦņȪū0Āèá.>, ǟǑȘȥĊǩ.0Õȳǥ/Ȓ90%0Œī yǪǥÍ9?^15-17). ÕȳǥəǤMG`pGu¹⁶⁾.əǤErRqVmɗ=@)

?, ®ɭNjŌȈ.<>Ǡšƥ.ÈǤƜʍnjȷ/ƫǤɔǗCȄƓ ?Ľ-ýÝ

Ę--. ȇ2ȅ*0ŴƅĄĊƋŐƟĊʀ‹ěǟʑÕȳĂǽ*2017Ĭ7*/ɹÐ 10Ĭʌ.xƝƫǤCɂ&#ÕȳŒīyǪǥ(oral squamous cell carcinoma, z: OSCC) Ǡš/NJŀ.')ȶĮțɔĊǩƕɕCɂ, ȇ1ȅ/ǵȂŎƍ/ƀǔŅ.')ƕ ɕCÃ#.

ēēɤ<2űƬ

2006Ĭ4ſ1Ŵ=2016Ĭ3ſ31Ŵ7*/10Ĭʌ.ŴƅĄĊƋŐƟĊʀ‹ěǟ ʑÕȳĂǽCÔə, ÕȳĂǽĊɠı.)ƫǤCɂ&#OSCCǠšCēɤ+#. ĵ ǽ.Ôə#OSCC 147š/%xƝƫǤCɂ&#110š.'), əŰŻĬʵ, Ņº, Ôəșɬ, ǟŇƃʌ, Ïǧĥ/ǧǓʀ“, Stage¶ʯ, ƫǤƬ, ƫǤŎȣ.')əǤʉ Cǔ)ĻAá.ƕɕCɂ&#. TNM¶ʯ+Stage¶ʯ.ʍ)0Union for

International Cancer Control (UICC) .<?TNM Classification of Malignant Tumors, 8th

editionCǔ#. 5ĬȕȁǓĉǎ/ȋµ.0Kaplan-MeierƬCǔ, ȋµ.ʙŠǟƢ

0Ŕ·>š, ‚Ļ{Ÿš0Ƣ…ŕ+#. Üȧʌ/Ǔĉǎ/ƀʼnħƕČ0log-rankƕ Č.)ɂ, P<0.05Cƀʼnħ>+#.

-, ƅǵȂ0ŴƅĄĊƋŐƟĊʀ¦ǑĒƏćè/Ŗɝ(ŖɝǚÚ˃EC 16-028)C Ľ)ɂ&#.

Ț Țƍ

ʼʺĬʵvŅº(Table 3)

ņȪ/Ņº0, ǖŅ64š(58.2%), ĆŅ46š(41.8%)*, ǖĆƦ01.4˃1*ǖŅ.ă

¨á*&#.

əŰŻĬʵ0ǖŅ27Ơ=85Ơ*īöĬʵ063.813.1Ơ, ĆŅ027Ơ=87 Ơ*īöĬʵ064.913.5Ơ*&#. ®–/īöĬʵ064.213.2Ơ*&#. Ĭʵ

¶Ĩ*060ƠŒ40š(36.4%)+ă, 60˅70ƠŒ/ņȪ/ÁÝ070š(63.6%)*&

#.

ʽʺÔəșɬ(Table 4)

ƟǽəǤő=/ȗ‰82š(74.5%)*ž:ă, xȹəǤő=/ȗ‰10š

(9.1%), ȷʑŠǽœʫ5š(4.6%), Dƕə5š(4.6%), ǬŠƉʑ4š(3.6%)*

&#.

ʾʺǟŇƃʌ(Table 5)<2ǠNj(Table 6)

ǟŇƃʌ01ſy3ſƄƼ48š(43.6%)*ž:ă, 3ſy6ſƄƼ 19š(17.3%), 12ſy16š(14.5%), 1ſƄƼ11š(10.0%)*&#. ǠNj 0ǝǡ45š(40.9%)+žă*, Ɲ*ǨŮ23š(20.9%), ǁǢ14š(12.7%), ȴǣ 6š(5.5%), ŘƟȃƫǦ{®5š(4.6%), ȴȲ4š(3.7%)*&#. !/5, ɼ çŋ, =', µɁ-,8=@#.

ʿʺÏǧĥ/ǧǓʀ“(Table 7)

Ïǧĥ/ǧǓʀ“0ȸ59š(53.6%)*ž:ă, zʬƟȬ20š(18.2%), ʧȏȵ12

š(10.9%), yʬƟȬ10š(9.1%), Õį5š(4.6%), ǶÕȽ4š(3.6%)*&#. ˀʺTNM¶ʯ(Table 8)<2Stage¶ʯ(Table 9)

T¶ʯ0T135š(31.8%), T250š(45.4%), T36š(5.5%), T419š(17.3%) *

>, T2Ǡšž:ă&#. N¶ʯ*0N090š(81.8%), N112š(10.9%), N2 8š(7.3%)*N0Ǡšž:ă, N30ɝ9=@-&#. M¶ʯ0®ǠšM0*&#. ʀ“º/T¶ʯ*0ȸ, yʬƟȬ, Õį, ʧȏȵ.)ȒÊūT2Ǡš*>, z ʬƟȬ.)070.0%T4Ǡš*&#.

Stage¶ʯº*0, Stage34š(30.9%), Stage42š(38.2%), Stage12š

(10.9%), Stage22š(20.0%)*>, Stagež:ăɝ9=@#.

ˁʺƫǤƬ(Table 10)

xƝƫǤ+)ɾř@#ƫǤƬ0, œɃǤƬÌnj52š(47.3%), ÇĊǤƬÌnj 31š(28.2%), ÇĊǤƬʸœɃǤƬ16š(14.5%), ÇĊǤƬʸŨĕȠǤƬ7š(6.4%), œɃǤƬʸŨĕȠǤƬ2š(1.8%), ŨĕȠǤƬÌnj<2œɃǤƬʸÇĊǤƬʸŨ ĕȠǤƬ!@"@1š(0.9%)*&#.

Stage¶ʯº/ƫǤƬ*0Stage*0œɃǤƬÌnj26š(76.5%)*ž:ă, ÇĊ

ǤƬÌnj5š(14.7%), ÇĊǤƬʸŨĕȠǤƬ3š(8.8%)*&#. Stage*0œɃ

ǤƬÌnj18š(42.9%)*ž:ă, ÇĊǤƬÌnj15š(35.7%), ÇĊǤƬʸœɃǤ Ƭ6š(14.3%), ÇĊǤƬʸŨĕȠǤƬ2š(4.7%), ŨĕȠǤƬÌnj1š(2.4%)*

&#. Stage*0ÇĊǤƬÌnj7š(58.3%), œɃǤƬÌnj<2ÇĊǤƬʸœɃ ǤƬ!@"@2š(16.7%), œɃǤƬʸŨĕȠǤƬ1š(8.3%)*&#. Stage*0 ÇĊǤƬʸœɃǤƬ8š(36.4%), œɃǤƬÌnj6š(27.3%), ÇĊǤƬÌnj4š

(18.2%), ÇĊǤƬʸŨĕȠǤƬ2š(9.1%), œɃǤƬʸŨĕȠǤƬ<2œɃǤƬʸ

ÇĊǤƬʸŨĕȠǤƬ!@"@1š(4.5%)*&#.

˂ʺƫǤŎȣ

®Ǡš/5ĬȕȁǓĉǎ0, ®–*66.2%*>, ǖŅ70.2%, ĆŅ060.5%*

&#(Table 11).

Stage¶ʯº*0Stage64.6%, Stage72.4%, Stage67.9%, Stage59.4%

*&#(Table 10). ǟƃ+/5ĬȕȁǓĉǎ.țɔĊǩƀʼnħ0ɝ9=@-&#.

ȩ ȩđ

2018Ĭ/Ƥʖ*Bò.?ÕȳǥȦņȪ0ˆÕ/ʲʵÇ.&)Āèá*

?+ȩ=@)?. ĬʵɞŬ.<?ǖĆƦ03˃2+ǖŅ.ă+@)>^15-17), ƅ ǵȂ/Țƍ.):1.4˃1+ǖŅ.ă¨á*&#. 7#, Ĭʵ¶Ĩ060ƠŒ.

ewO?+@)?¹⁸⁾, ƅǵȂȚƍ.):ɹÐ/üå^18-22)+ßƘ.60Ơ

Œ.ewOCɝ9#.

Ôəșɬ.')0ɹÐ/üå^{21, 23)}.<?+ÊūyƟǽ=/ȗ‰*?+

@)>, ƅǵȂȚƍ.):74.5%ƟǽəǤő=*>, ĵʑŠəǤǽ=/

ȗ‰:ÝB ?+79.1%Ɵǽ=/ȗ‰*&#. /+=Õȳǥ/ǧɌ.0 ƟǽÈĩʄɋ-ĹÁCƍ#)?+ȩ=@?.

ǟŇƃʌ03ſ±ž:ă+/üå^{21, 23)}?. ƅǵȂ.):3ſƄ Ƽ/Ôə59š(53.6%)+ž:ă8=@#. 7#, Š/üå^21,23)+ßƘ.Stage¶ʯ +/ʌ.NJº-ǭʍʍŸ0ɝ9=@-&#.

ǠNj0, ǝǡ, ȴȲ, ȴǣĶŎ, ǁǢĶŎă+@)?²⁴⁾. ƅǵȂ.)0

ǝǡ40.9%, ǨŮ20.9%, ǁǢ12.7%+ă8=@, ȴǣ05.5%, ȴȲ03.7%.

+,7&)#. Š/üå^{21, 23)}.)ǨŮ010%ƄƼ*?, ƅǵȂ.)0

20.9%+ăɝ9=@#. ǨŮ23š/%15š(65.2%)0ƟǽəǤő.)ǨŮCŝţ

@ĵǽ3ȗ‰+-&)>, ƟǽÈĩ/ȏȵǟā3/ʼnɡáy)?+šđ

@#.

Ïǧĥ/ǧǓʀ“02013Ĭ/ŴƅʨʩʀǥĊ/ʝɔ¹⁸⁾*0, ȸ55.1%, zʬƟȬ 13.9%, Õį9.2%, ʧȏȵ8.9%, yʬƟȬ7.3%, ǶÕȽ2.6%, Õê1.0%+üå@)

?. ƅǵȂ*0ȸ53.6%*ž:ă, zʬƟȬ18.2%, ʧȏȵ10.9%, yʬƟȬ 9.1%, Õį4.6%, ǶÕȽ3.6%*&#.

ǟƃ¶ʯ/¶Ĩ0õú;Ųɗ.<&)Ƙ *?, T2, StageǠšă+@

)>, ɲĬ0Stage, Stage/¸ƃǥɹÊūCÍ9?+B@)?¹⁷⁾. ƅǵȂ

*0T245.4%+ž:ă T131.8%, T417.3%, T35.5%*>, ¸ƃǥ 77.2%+ăɝ9=@#.

Õȳǥ0, ȸ, Õį, ʧȏȵ, yʬƟȬ, zʬƟȬ, ǶÕȽ-,ɐ¾ĊǩƗɵ/Ǜ-

&#ʀ“.ǧǓ?#9., ȴǢ/ǟŌ;ɷĚƘij0Üʀ“.<&)Ǜ->, ƫǤƬ :Üʀ“.<&)Ǜ-&)?. œɃǤƬ.)0, æì<2Ţʰvëz, Ɨʣ-

,/ƜȰʢ+ʬʭʢʦú/Ŭďʢ.ĸʤCÒ6#9, ƫǤĻ/ņȪ/QOL CʄɎ

#ƫǤ–ȑƂ7@?. ƅǵȂ.)xƝƫǤ+)ɾř@#ƫǤƬ0, œɃ

ǤƬÌnj52š(47.3%), ÇĊǤƬÌnj31š(28.2%), ÇĊǤƬʸœɃǤƬ16š

(14.5%)*>, ŠŲɗ/üå^19-31)+Ʀɰ?+ÇĊǤƬÌnjă¨á.&#.

OSCC/ƫǤŎȣ.')0, ®Ǡš.)039.1˅84.3%, Stageº*0Stage 71.4˅100%, Stage63.0˅92.0%, Stage52.4˅88.4%, Stage14.0˅81.1%+

/üå20-23, 25-30)?. ƅǵȂ.?5ĬȕȁǓĉǎCŠŲɗ/üå+Ʀɰ?+

®Ǡš, Stage˅0ɹÐ/üå+ßƘ/Țƍ*&#. Stage64.6%+”Țƍ+

-&#, Stage.?ÏǟƢ01š/8*&#. ƅǵȂ.)05ĬȕȁǓĉ ǎ/ȋµ.ʙ‚Ļ{ŸšCƢ…ŕ+)>, Stage.)‚ĻǷɝ×Ȱ-

Ǡš/8*5ĬȕȁǓĉǎCȋµ?+94.4%*&#+=, ȋµƬ.<?ħ*

&#+ȩ=@#. 7#|ģ=²²⁾0ƒƫǩƫǤȧ/5ĬȕȁǓĉǎ63.7%, ®Ǡš*0

58.9%+ĻȪ.?Ǔĉǎ/”zCɝ9)>, țɔ´Ǒ/ħǛ0ƫǤ/ƒƫŅ.

<&):Ǔĉǎ.ħǓ?DŽ.ǘʼn4*?+)?.

xƝƫǤĻ/³ǧǠš036š*>, 28š.ɳÃƫǤɂB@, 8šɮÈ*&#.

ƅǵȂ.?Ƣ…Ǡš07š*>, ÏǟƢ04š*&#. ÏǟƢǠš/Stage¶

ʯ0Stage1š, Stage1š, Stage2š*&#. Stage/Ƣ…š0ʩʀqu

dȍĻǧɮǾ.<?:/*>, Stage/Ƣ…š0Ïǧĥ/³ǧ, Stage0¸ǧǟā

/»ľ{×1š, ĻǧɮǾ.<?:/1š*&#. 7#, ‚Ļ{Ÿš021š*,

Šʑ3ɮÈ10š, ƄƉʑ10š, ɴʑïʞ.)|Ű1š*&#. ŵƃǧɌvŵ ƃƫǤ/ʄɋŅC³Ƿɝ?++:., Ïǧĥ.ē?ƫǤ.Ã, ĻǧɮǾ:ȩō

#¸íƫǤ/ƒƫŅʄɋ*?+ȩ=@, Äƍǩ-ƫǤŏǙCƕɕ)ł ɋ?+ȩ=@#.

-B%, ƅǵȂ.û(, ʩʀqudȍɮǾCȸǥ/ȴǢʌɨ.?qu

dȌ/Íƀǎ/ĀÃ.ǰǫ#ǟǑȘȥəŰCȶĮ.ńǔ*@1, ƅȅ*ɝ9=@

#ʩʀqudȍĻǧɮǾCʏ, Äƍǩ*ƒƫŅ/ʲƫǤ/ȄƓ.'-?+ȩ

=@#.

Ț Țɟ

2006Ĭ4ſ=2016Ĭ3ſ/10Ĭʌ.ŴƅĄĊƋŐƟĊʀ‹ěǟʑÕȳĂǽCÔ ə, ÕȳĂǽĊɠı.)ƫǤCɂ&#ÕȳŒīyǪǥǠš.')ƕɕCɂüå

#.

ēɤǠš0110š*>, ǖĆƦ01.4˃1*ǖŅ.ă, īöĬʵ064.213.2Ơ

*&#. Ïǧĥ/ǧǓʀ“0ȸ59š(53.6%)*ž:ă, TNM¶ʯº*0T2, N0, M0!@"@žă*&#. Stage¶ʯº*0Stage42š(38.2%)+ă, ƫǤƬ0

Stage, *0ĂǽǤƬC|Ł., Stage, *0ÇĊǤƬ;ŨĕȠǤƬCȘ8ÝB

#ƫǤƬɾř@, ®Ǡš/5ĬȕȁǓĉǎ066.2%*&#.

ņȪ/®ɭNjŌ, QOLCȩō#y*, ƒƫŅ/ʲÄƍǩ-¸íƫǤCȄƓ?

+ʄɋ*?+ȩ=@#.

Table 3 ĬʵŅºǠšū

Table 4 Ôəșɬ

Table 5 ǟŇƃʌ

Table 6 ȶĮǠNj

Table 7ʀ“ºǧǓū+T¶ʯ

Table 8 TNM¶ʯ/±ɘ

Table 9 Stage¶ʯºǠšū

Table 10 Stage¶ʯºƫǤƬ

! $

$

#! ! "!

Table 11 ®Ǡš<2ǖĆº/5ĬȕȁǓĉǎ

Table 12 Stage¶ʯº5ĬȕȁǓĉǎ

Ȟ ȞŜ

ÕȳŒīyǪǥ.), ‚Ļ.ĸʤ?ʄɋ-îĈ/x'0, ʩʀqudȍɮǾ

/ƀDž*>, ʩʀqudȍɮǾC‚ƺ?+0ƫǤƬ/ɾř.ʄɋ*?. !

*ƅǵȂ*0, ÕȳŒīyǪǥ/ȴǢʌɨ.?qudȌ+ʩʀqudȍɮǾ+/

ʍɶŅCƕȔ#. ȇ1ȅ*0qudȌ/ĶŌɔʆĊǩƕɕ+), ȸǥ.)ȴ Ǣʌɨ/qudȌÍƀǎ, ʢȁ, ĶŌ, ū.')ƺČ, ɮǾȧ+ʡɮǾȧ/2ȧ.

¶)ƦɰƕɕCɂ-&#. ȇ2ȅ*0, ʩʀqudȍɮǾ/‚ƺ+)ȶĮńǔC ǫŝ, ŴƅĄĊƋŐƟĊʀ‹ěǟʑÕȳĂǽ.?xƝƫǤǠš.')ȶĮț ɔĊǩƕɕCɂ&#.

@=/ǵȂ=, ȸǥȴǢʌɨ.)ɮǾȧ*0qudȌÍƀǎ0ĀÃ, ų ĉ/qudȌ/‘ĚśĴǸ@#. ‘ĚśĴ#qudȌ0, qudȌ±ǪȖȯʌ /ŠǰȎ.->, !/ʌʘȴǢȖȯ/ž­;ǒÿ+-?+*, qudȍ ɮǾ3+'-?+šđ@#.

ƅǵȂ.û(, ʩʀqudȍɮǾCȸǥ/ȴǢʌɨ.?qudȌ/Íƀ ǎ/ĀÃ.ǰǫ#ǟǑȘȥəŰ0, ʩʀqudȍĻǧɮǾCʏ, ƒƫŅ/ʲƫ Ǥ/ȄƓ.'-?+ȩ=@?.

ÑȩŭǍ

1) Yamamoto N, Sato K, Yamauchi T, et al: A 5-year activity report from the Oral Cancer

Center, Tokyo Dental College, Bull Tokyo Dent Coll: 54(4): 265-73, 2013

2) Zhao D, Pan J, Li XQ, Wang XY, et al: Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance, J Oral Pathol Med, 37(10): 616-25, 2008.

3) Japan Society for Oral Tumors, General rules for clinical and pathological studies on oral

cancer. 1st ed, 30-35, JSOT, Tokyo, 2010.

4) Barnes L, Eveson JW, Reichart P, et al: World Health Organization classification of

tumours: pathology and genetics of head and neck tumours, 168-75, IARC Press, Lyon,

France, 2005.

5) Yamamoto E, Miyakawa A, Kohama G: Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity, Head Neck Surg, 6: 938-47, 1984.

6) Winn DM, Diehl SR, Horowitz AM, et al: Scientific progress in understanding oral and

pharyngeal cancers, K Am Dent Assoc, 129(6): 713-18, 1998.

7) Sung K, Kim SM, Myoung H, et al: The effectiveness of elective neck dissection on early

(stage I, II) squamous cell carcinoma of the oral tongue. J Korean Assoc Oral Maxillofac

Surg, 43(3): 147-51, 2017.

8) Otsuru M, Aoki T, Ota Y, et al:Is an Elective Neck Dissection Necessary for All Cases of

N0 Oral Squamous Cell Carcinoma? ʹElective Neck Dissection may be Performed for

Tongue Cancer with Tumor Thickness More than 4 mmʹ, Tokai J Exp Clin Med, 41(3):

112-17, 2016.

9) Toshiyuki Inomata, Tadahiko Utsunomiya, Masaaki Suemitsu: A Histopathological and

Immunohistochemical Study of Vascular localization on Schwannoma in the

Oro-maxillofacial Region, Int J of Oral-Med Sciences, 9(3): 159-66, 2011.

10) Masaaki Suemitsu: A Pathomorphological Study of Fractal Analysis in

Parenchymal-stromal Border on Keratocystic Odontogenic Tumor ʹ with Special

Reference to Proliferative Activity and Vascular Distributionʹ, Int J Oral-Med Sci, 10(4):

372-83, 2012.

11) Inoue M, Roan CH, Abe T, et al: Localization and characterizeation of lymphatic vessels in

oral and cervical squamous cell carcinoma, Exp Ther Med, 2(5): 793-97, 2011.

12) Agarwal D, Pardhe N, Bajpai M, et al: Characterization, Localization and Patterning of

lymphatics and blood vessels in oral squamous cell carcinoma: A comparative study using

D2-40 and CD34 IHC marker, J Clin Diagn Res, 8(10): 86-89, 2014.

13) Watanabe S, Kato M, Kotani I, et al:Lymphatic Vessel Density and Vascular Endothelial

Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A

Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40,

VEGF-C and VEGF-D, Yonago Acta Med, 56(1): 29-37, 2013.

14) George ML, Tutton MG, Janssen F, et al: VEGF-A, VEGF-C, and VEGF-D in colorectal

cancer progression, Neoplasia, 3(5): 420-27, 2001.

15) Hori M, Matsuda T, Shibata A, et al.: Cancer incidence and incidence rates in Japan in

2009: a study of 32 population-based cancer registries for the Monitoring of Cancer

Incidence in Japan (MCIJ) project, Jpn J Clin Oncol, 45(9): 884-891, 2015.

16) ŴƅÕȳȴǢĊ ÕȳǥƫǤMG`pGuŦɓćè, ŴƅÕȳĂǽĊ Õ

ȳǥəǤMG`pGuȊČćè Ýßćè: ǽĊǩƒŚ.û(ÕȳǥəǤ

MG`pGu, 2013ĬLj, 11-13, ʇϵLjƑijǹ, Ɗ†, 2012.

17) ƀÞʟ¼, ġÏũÛ, ėƈ§5: 2002 Ĭİ(ǹ)ŴƅÕȳĂǽĊŝČǵ¢ƃʌC

Ôə#ʬÕȳʦú/ňŅȴǢ.ʍ?ǜĊǩǵȂ, ŴÕĂɜ, 52(7): 401-410,

2006.

18) Hayashi R, Nishio M, Kato T: Report of Head and Neck Cancer Registry of Japan Clinical

Statistics of Registered Patients, 2011, Japanese Journal of Head and Neck Cancer,

39(Supplement): 15-32, 2013.

19) Ùɲ‡Ĉ, ĝz˜ʛ, Ļɀŷź5: ɹÐ10Ĭʌ/ʬÕȳʦúňŅȴǢ/ȶĮțɔ,

ÕȳȴǢ, 14(2): 37-43, 2002.

20) ėƨ¿Ø, ƐǕƲ, ĄþŸĈ5: ĵǽ.?ʬÕȳʦúňŅȴǢxƝǠš/ȶ

ĮțɔĊǩƕɕ, ¡ĤÈɜ, 51(1): 15-23, 2003.

21) á„Ʈ, ƆÏxƞ, ÞǕʜÛ5: ňŅȴǢņȪ/ĵǽ.?ȶĮțɔǩƕɕ

žɲ15Ĭʌ/285š.'), ÕȳȴǢ, 5(1): 19-28, 1993.

22) |ģƭĬ, ɣǕȓxƁ,  ǕȼƁ5: ʬÕȳʦúňŅȴǢ/ɹÐ10Ĭʌ/ȶĮ

țɔ, ÕȳȴǢ, 5(1): 60-69, 1993.

23) ĄƛǺǓ, džɢȅĈ, ŹǼƚ5: ĵǽ*ƫǤCɂ&#ɹÐ10Ĭʌ.B#?Õȳʦ

úŒīyǪǥ/ȶĮțɔĊǩƕɕ, ÕȳȴǢ, 28(2): 41-48, 2016.

24) ǨǴ°«, Öʂĭķ: ÕȳĂǽĊ ȇ 3 Lj, 253-255, ÈƟȿµLjƑijǹ, Ɗ†,

2014.

25) ʐʀÎ, ŽɀǧŸ, ó„ȜŃ5: àÖęşƹǟʑƟǽÕȳĂǽ.?ɹÐ 8

Ĭʌ/ÕȳǥǠš/ȶĮǩƕɕ, ŊʑĄƟɜ, 54(4): 459-465, 2016.

26) ĄʔȢʃĈ, •ɀŭķ, ƪÏIJ5: ĞʎǮȄăƫɌǟʑƟǽÕȳĂǽ.?ɹ

Ð21Ĭʌ/ÕȳŒīyǪǥ/ȶĮǩƕɕ, ŊʑĄƟɜ, 51(1): 25-30, 2013.

27) Ďz¿, ƒĠŸǼ, |ŽƒȺƚ5: ĵǽ.?ÕȳňŅȴǢǠš/ȶĮțɔǩ

ƕɕ, Kitakanto Med J, 58: 167-172, 2008.

28) Ƌ„Ȩɿ, ĄʅIJ‡, ƋƱ«Ʈ5: ÕȳŒīyǪǥxƝǠš/ƫǤŎȣ/ƕɕ,

źƟɜ, 24: 277-286, 2004.

29) ɊǕ«ǖ, ċǕǯ€, ĝƈÂ5: 10 Ĭʌ/ÕȳȏȵŒīyǪǥ/ȶĮǩƕɕ, Õ

ȳȴǢ, 14(3): 71-77, 2002.

30) ƔǂʕɆ, }ğʟ, ĝĢË5: ʬÕȳʦúňŅȴǢ/ȶĮțɔǩɏđ, Õǽɜ,

43(2): 292-296, 1994.

31) ƻǕÎÛ, LJğDZĈ, ȄƋƞɍ5: Õȳǥ/ȶĮțɔ, ȫʴȶĮ, 95: 933-937,

2002.

Ñȩɟŭ

ƅɟŭ0, ~+-?ÑȩɟŭMorphometric analysis of tumor stromal lymphatic vessels and

lymphangiogenesis in oral squamous cell carcinomaJournal of Oral and Maxillofacial Surgery, Medicine, and Pathology˃Vol. 31(1), 2019. <2À+-?ÑȩɟŭɹÐ10Ĭʌ.Ŵ ƅĄĊƋŐƟĊʀÕȳĂǽĊɠı*ƫǤ#ÕȳŒīyǪǥ/ȶĮțɔĊǩƕɕŴ ĄÕȳǽĊ˃Vol. 44 (1), 1-7, 2018. C7+9#:/*?.